ARVN — Arvinas, Inc.

Summary of Arvinas Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of September 30, 2025, Arvinas reported approximately $787.6 million in cash, cash equivalents, and marketable securities, down from $1.04 billion at the end of 2024.
• Revenue: Q3 2025 revenue totaled $41.9 million, a decrease from $102.4 million in Q3 2024, primarily due to the conclusion of revenue recognition from a Novartis license agreement, offset by a $20 million milestone payment from Novartis.
• Expenses: General and administrative expenses were $21 million, significantly reduced from $75.8 million in the prior year, largely due to the termination of a lease and reduced personnel costs. Research and development expenses were $64.7 million, down from $86.9 million year-over-year.
• Stock Repurchase: The Board authorized a $100 million stock repurchase program, with approximately 2.56 million shares repurchased at an average price of $7.91 per share.

2. Strategic Updates and Business Highlights

• Pipeline Progress: Arvinas highlighted significant advancements in its clinical pipeline, including promising data from ARV-102 (LRRK2 degrader) and ARV-393 (BCL6 degrader). The company is also advancing ARV-806 (KRAS G12D degrader) and ARV-027 (targeting polyQ-AR) into clinical trials.
• Partnerships: Arvinas is collaborating with Pfizer to select a third party for the commercialization of vepdegestrant, which is under FDA review with a PDUFA date of June 5, 2026.
• Upcoming Data: The company anticipates multiple data readouts in the coming months, including presentations at major conferences.

3. Forward Guidance and Outlook

• Financial Guidance: Arvinas expects to maintain a quarterly run rate below $75 million in expenses, aiming for total non-GAAP expenses below $300 million in fiscal year 2026. The cash runway is projected to extend into the second half of 2028.
• Clinical Development Plans: The company plans to initiate a Phase Ib trial for ARV-102 in progressive supranuclear palsy (PSP) in the first half of 2026 and is preparing for additional trials for its other candidates.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The significant drop in revenue year-over-year raises concerns about the company’s financial health and reliance on milestone payments.
• Clinical Development Risks: While early data for several candidates are promising, the company has not yet achieved predicted efficacious exposure levels in ongoing trials, particularly for ARV-393.
• Market Competition: The competitive landscape for oncology and neurology therapeutics is intensifying, with several companies developing similar PROTAC technologies, which could pressure Arvinas' market position.

5. Notable Q&A Insights

• ARV-393 Differentiation: The management emphasized the potential for ARV-393 to differentiate itself in the market, particularly in combination therapies for non-Hodgkin lymphoma.
• ARV-102 Expectations: Questions regarding the LRRK2 program highlighted the importance of biomarker data in translating to clinical benefits, with expectations for significant reductions in biomarkers associated with neurodegeneration.
• Combination Strategies: The company is exploring combination therapies for ARV-806 and is optimistic about the potential for these combinations to enhance therapeutic efficacy while minimizing toxicity.
• HPK1 Program: There is enthusiasm around the HPK1 degrader, with expectations for more preclinical data to be shared soon, indicating its potential in immuno-oncology.

Overall, Arvinas is navigating a dynamic period with a strong pipeline and strategic partnerships, but faces challenges in revenue generation and competitive pressures in the biotech landscape.